0001567619-21-017896.txt : 20211005 0001567619-21-017896.hdr.sgml : 20211005 20211005141122 ACCESSION NUMBER: 0001567619-21-017896 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211001 FILED AS OF DATE: 20211005 DATE AS OF CHANGE: 20211005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Welgus Howard G. CENTRAL INDEX KEY: 0001801050 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39186 FILM NUMBER: 211306064 MAIL ADDRESS: STREET 1: C/O ARCUTIS BIOTHERAPEUTICS, INC. STREET 2: 2945 TOWNSGATE ROAD, SUITE 110 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001787306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 812974255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 BUSINESS PHONE: 805-418-5006 MAIL ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 FORMER COMPANY: FORMER CONFORMED NAME: Arcutis, Inc. DATE OF NAME CHANGE: 20190905 4 1 doc1.xml FORM 4 X0306 4 2021-10-01 0 0001787306 Arcutis Biotherapeutics, Inc. ARQT 0001801050 Welgus Howard G. C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD, SUITE 300 WESTLAKE VILLAGE CA 91361 1 0 0 0 Common Stock 2021-10-01 4 M 0 2500 0.5802 A 184396 D Common Stock 2021-10-01 4 S 0 2500 23.8719 D 181896 D Common Stock 24991 I By Trust Stock Option (Right to Buy) 0.5802 2021-10-01 4 M 0 2500 0.00 D 2028-06-13 Common Stock 2500 22606 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The transaction was executed in multiple trades in prices ranging from $23.23 to $24.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. The option began vesting monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. /s/ Scott Burrows, as Attorney-in-Fact for Howard G. Welgus 2021-10-05